Want to see HK:9606 full AI Analyst Report?

Duality Biotherapeutics, Inc. (9606) Price & Analysis

5 Followers

9606 Stock Chart & Stats

HK$310.60

Market closed

HK$310.60

Day’s Range― - ―

52-Week RangeHK$158.50 - HK$563.50

Previous CloseN/A

VolumeN/A

Average Volume (3M)1.60M

Market Cap

HK$19.56B

Enterprise ValueHK$12.78B

Total Cash (Recent Filing)HK$3.70B

Total Debt (Recent Filing)HK$67.89M

Price to Earnings (P/E)―

Beta1.38

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding90,875,210

10 Day Avg. Volume2,424,103

30 Day Avg. Volume1,602,164

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)7.19

Price to Sales (P/S)9.67

P/FCF Ratio96.49

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$489.12

Price Target Upside57.47% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PositionThe company maintains a solid cash balance of RMB3.75bn, which is sufficient to support continued R&D and pipeline expansion.

Industry RecognitionDualityBio's high-profile partnerships serve as industry validation of its platform and pipeline assets.

PartnershipsDualityBio's extensive partnerships with companies like BioNTech and GSK, totaling over US$6.0bn in potential deal value, are expected to provide sustained funding as clinical programs progress.

Pipeline InnovationDualityBio has a robust pipeline of in-house discovered antibody-drug conjugate (ADC) candidates which is a testament to the Company's prowess in ADC innovation.

Bears Say

Commercialization TimelineBioNtech and DualityBio plan to file NDAs for DB-1303/BNT323 in the US and China by end-2025, marking a major step towards commercialization.

Duality Biotherapeutics, Inc. News

Duality Biotherapeutics Gains Shareholder Backing for Governance and Capital Mandates

The latest announcement is out from Duality Biotherapeutics, Inc. ( ($HK:9606) ). Duality Biotherapeutics, Inc. is a Cayman...

9d ago

9606

Duality Biotherapeutics Grants RSUs to Key Staff Under 2025 Share Scheme

Duality Biotherapeutics, Inc. ( ($HK:9606) ) just unveiled an update. Duality Biotherapeutics has granted 283,500 restricted share units...

9d ago

9606

Duality Biotherapeutics Revamps Company Secretarial and Governance Structure in Hong Kong

The latest update is out from Duality Biotherapeutics, Inc. ( ($HK:9606) ). Duality Biotherapeutics has reshuffled its corporate...

9d ago

9606

Duality Biotherapeutics Wins SSE Acceptance for Planned RMB Share Issue

Duality Biotherapeutics, Inc. ( ($HK:9606) ) has shared an announcement. Duality Biotherapeutics, Inc. has had its application materials...

23d ago

9606

Duality Biotherapeutics Advances Plan for RMB Share Listing on Shanghai Sci-Tech Board

Duality Biotherapeutics, Inc. ( ($HK:9606) ) just unveiled an announcement. Duality Biotherapeutics said it is progressing plans to...

25d ago

9606

Duality Biotherapeutics Sets 2026 AGM With Capital Mandates on Agenda

Duality Biotherapeutics, Inc. ( ($HK:9606) ) has issued an update. Duality Biotherapeutics has called its annual general meeting...

1M ago

9606

Duality Biotherapeutics Launches US$40 Million Buyback as Chairman Plans Stake Increase

Duality Biotherapeutics, Inc. ( ($HK:9606) ) just unveiled an update. Duality Biotherapeutics has authorized a share repurchase plan...

2M ago

9606

Duality Biotherapeutics Exercises U.S. Cost and Profit-Sharing Option for BioNTech ADC

The latest announcement is out from Duality Biotherapeutics, Inc. ( ($HK:9606) ). Duality Biotherapeutics has exercised its exclusive...

2M ago

9606

Duality Biotherapeutics Wins Shareholder Approval for RMB Share Issue and Sci-Tech Board Listing

Duality Biotherapeutics, Inc. ( ($HK:9606) ) has provided an update. Duality Biotherapeutics, Inc., a Cayman Islands-incorporated biopharmaceutical company...

2M ago

9606

Duality Biotherapeutics Calls EGM to Approve RMB Share Issue and Sci-Tech Board Listing Framework

An update from Duality Biotherapeutics, Inc. ( ($HK:9606) ) is now available. Duality Biotherapeutics has convened an extraordinary...

3M ago

9606

9606 FAQ

What was Duality Biotherapeutics, Inc.’s price range in the past 12 months?

Duality Biotherapeutics, Inc. lowest stock price was HK$158.50 and its highest was HK$563.50 in the past 12 months.

What is Duality Biotherapeutics, Inc.’s market cap?

Duality Biotherapeutics, Inc.’s market cap is HK$19.56B.

When is Duality Biotherapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Duality Biotherapeutics, Inc.’s earnings last quarter?

Currently, no data Available

Is Duality Biotherapeutics, Inc. overvalued?

According to Wall Street analysts Duality Biotherapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Duality Biotherapeutics, Inc. pay dividends?

Duality Biotherapeutics, Inc. does not currently pay dividends.

What is Duality Biotherapeutics, Inc.’s EPS estimate?

Duality Biotherapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Duality Biotherapeutics, Inc. have?

Duality Biotherapeutics, Inc. has 90,875,210 shares outstanding.

What happened to Duality Biotherapeutics, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Duality Biotherapeutics, Inc.?

Currently, no hedge funds are holding shares in HK:9606

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Duality Biotherapeutics, Inc. Stock Smart Score

Underperform

Analyst Consensus

Moderate Buy

Average Price Target:
HK$489.12 (57.47% Upside)

Top Smart Score Stocks >

Company Description

Duality Biotherapeutics, Inc.

Operating as a clinical-stage enterprise, Duality Biotherapeutics, Inc. concentrates on pioneering next-generation antibody-drug conjugate (ADC) therapies and proprietary duality immune toxin antibody conjugate (ITAC) solutions. The firm was founded by Zhu Zhong Yuan on July 3, 2019, and its main offices are situated in Shanghai, China.

Duality Biotherapeutics, Inc. (9606) Earnings & Revenues

Historic Earnings Reports

9606 Stock 12 Month Forecast

Average Price Target

HK$489.12

▲(57.47% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"180":"HK$180","521":"HK$521","265.25":"HK$265.3","350.5":"HK$350.5","435.75":"HK$435.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":520.49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$520.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":489.115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$489.12</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":457.74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$457.74</span>\n  </div></div>","useHTML":true}}],"tickPositions":[180,265.25,350.5,435.75,521],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,181.2,207.29923076923075,233.39846153846153,259.4976923076923,285.5969230769231,311.69615384615383,337.7953846153846,363.8946153846154,389.99384615384616,416.0930769230769,442.1923076923077,468.2915384615385,494.39076923076925,{"y":520.49,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,181.2,204.88576923076923,228.57153846153847,252.25730769230768,275.9430769230769,299.62884615384615,323.31461538461537,347.00038461538463,370.68615384615384,394.37192307692305,418.0576923076923,441.74346153846153,465.42923076923074,{"y":489.115,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,181.2,202.47230769230768,223.74461538461537,245.0169230769231,266.28923076923076,287.5615384615385,308.83384615384614,330.10615384615386,351.3784615384616,372.65076923076924,393.9230769230769,415.1953846153846,436.46769230769235,{"y":457.74,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":236.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":324.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":349.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":363.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":314,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":341.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":298.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":317.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":299,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":321.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":276,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":181.2,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >